Full Breakdown
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
8/13/2026, 8:39:52 PM
Legal Challenge Over Advertising
Novo Nordisk has filed a lawsuit accusing Eli Lilly of misleading consumers in ads that compare Lilly’s obesity drug Zepbound with an older, lower-dose version of Novo’s injectable Wegovy. The complaint argues that Lilly’s advertisements rely on a head-to-head trial published in *The New England Journal of Medicine* (May 2025) that used Wegovy’s 1.7 mg or 2.4 mg doses, while Novo now markets a higher-dose 7.2 mg formulation approved by the FDA in March 2026. Novo contends that the ads therefore do not present the “full picture” of Wegovy’s efficacy.
Competitive Landscape and Recent Approvals
The GLP-1 weight-loss market has intensified as both firms launch new products. Eli Lilly’s oral obesity drug Foundayo received FDA approval on April 1 2026 and began shipping shortly thereafter. Zepbound remains the most prescribed obesity medicine in the United States, and Lilly’s recent earnings report showed volume growth, though Foundayo missed expectations.
Official Statements & Responses
Mike Doustdar, Novo Nordisk’s chief executive, emphasized the need for “fair” competition and said the lawsuit seeks to ensure patients receive complete information before choosing a therapy. He noted that Novo’s shares have fallen about 6 % since the filing, while Eli Lilly’s stock has risen roughly 4 %, reflecting the competitive pressure. An Eli Lilly spokesperson countered that the company’s advertising is truthful, that no head-to-head trial directly pits Wegovy HD against Zepbound, and that Lilly stands behind its science.
Data & Statistics
- Trial cited by Lilly: Zepbound 10 mg/15 mg -> 20.2 % average weight loss (? 50 lb) over 72 weeks; Wegovy 1.7 mg/2.4 mg -> 13.7 % (? 33 lb).
- Novo’s internal 7.2 mg Wegovy study: ~19 % weight loss (? 47 lb) over 72 weeks.
- Market reaction: Novo Nordisk shares –6 %; Eli Lilly shares +4 % since suit filing.
